北京大学学报(医学版) ›› 2022, Vol. 54 ›› Issue (5): 936-942. doi: 10.19723/j.issn.1671-167X.2022.05.021
Chieko MORIMOTO,Yi-qin WANG,Rong ZHOU,Jian-liu WANG*()
摘要:
目的: 探讨子宫内膜非典型增生(complex atypical hyperplasia, CAH)及子宫内膜癌(endometrial cancer, EC)患者保留生育功能治疗的效果及妊娠结局。方法: 回顾性分析2009年1月至2021年9月北京大学人民医院进行保留生育功能治疗的EC患者及CAH患者共191例, 对患者的肿瘤缓解、复发及妊娠情况进行分析。结果: (1) 疗效及相关因素: 总体完全缓解(complete response, CR)率为86.1%(161/187例), CAH组的CR率显著高于EC组(92.7% vs. 79.1%, P=0.007), Logistic回归分析显示, CAH组的CR率更高(OR=2.786, P=0.035);(2)复发率: 总体复发率为19.3%(31/161例), EC组显著高于CAH组(26.4% vs. 13.5%, P=0.039), 中位复发时间为22.5(9.0, 50.0)个月; (3)复发相关因素: 病理类型为EC(χ2=4.880, P=0.027)、未使用二甲双胍(χ2=7.075, P=0.008)、治疗达CR的时间>7个月(χ2=6.204, P=0.013)及未妊娠(χ2=6.765, P=0.009)患者的累积复发率显著更高; (4)妊娠结局及相关因素: 达到CR的患者中共有108例有生育意愿, 妊娠率为41.7%(45/108例), 生育率为34.3%(37/108), EC组的生育率显著低于CAH组(28.6% vs. 42.4%, P=0.045), 中位妊娠时间为10.50(5.75, 33.25)个月。既往有妊娠史(OR=9.468, P < 0.001)和接受辅助生殖治疗(OR=7.809, P < 0.001)患者的妊娠率更高。结论: EC及CAH患者进行保留生育功能治疗的疗效肯定, 可以获得较高的疾病缓解率和一定的妊娠分娩率, 但仍存在复发率高及生育率低的问题。
中图分类号:
1 |
Corzo C , Barrientos SN , Westin SN , et al. updates on conservative management of endometrial cancer[J]. J Minim Invasive Gynecol, 2018, 25 (2): 308- 313.
doi: 10.1016/j.jmig.2017.07.022 |
2 |
中国研究型医院学会妇产科专业委员会. 早期子宫内膜癌保留生育功能治疗专家共识[J]. 中国妇产科临床杂志, 2019, 20 (4): 369- 373.
doi: 10.13390/j.issn.1672-1861.2019.04.025 |
3 |
Silverberg SG , Makowski EL , Roche WD . Endometrial carcinoma in women under 40 years of age: Comparison of cases in oral contraceptive users and non-users[J]. Cancer, 1977, 39 (2): 592- 598.
doi: 10.1002/1097-0142(197702)39:2<592::AID-CNCR2820390233>3.0.CO;2-O |
4 | Gynecologic Oncology Branch of the Chinese Medical Association . Guidelines for fertility-preserving treatment of gynecological malignant tumors (Chinese)[J]. Chin J Obstet Gynecol, 2014, 4, 243- 248. |
5 |
Park JY , Kim DY , Kim JH , et al. Long-term oncologic outcomes after fertility-sparing management using oral progestin for young women with endometrial cancer (KGOG 2002)[J]. Eur J Cancer, 2013, 49 (4): 868- 874.
doi: 10.1016/j.ejca.2012.09.017 |
6 |
Chen M , Jin Y , Li Y , et al. Oncologic and reproductive outcomes after fertility-sparing management with oral progestin for women with complex endometrial hyperplasia and endometrial cancer[J]. Int J Gynaecol Obstet, 2016, 132 (1): 34- 38.
doi: 10.1016/j.ijgo.2015.06.046 |
7 |
Hahn HS , Yoon SG , Hong JS , et al. Conservative treatment with progestin and pregnancy outcomes in endometrial cancer[J]. Int J Gynecol Cancer, 2009, 19 (6): 1068- 1073.
doi: 10.1111/IGC.0b013e3181aae1fb |
8 |
Wang CJ , Chao A , Yang LY , et al. Fertility-preserving treatment in young women with endometrial adenocarcinoma: A long-term cohort study[J]. Int J Gynecol Cancer, 2014, 24 (4): 718- 728.
doi: 10.1097/IGC.0000000000000098 |
9 |
Ohyagi-Hara C , Sawada K , Aki I , et al. Efficacies and pregnant outcomes of fertility-sparing treatment with medroxyprogesterone acetate for endometrioid adenocarcinoma and complex atypical hyperplasia: Our experience and a review of the literature[J]. Arch Gynecol Obstet, 2015, 291 (1): 151- 157.
doi: 10.1007/s00404-014-3417-z |
10 |
Gunderson CC , Fader AN , Carson KA , et al. Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review[J]. Gynecologic Oncology, 2012, 125 (2): 477- 482.
doi: 10.1016/j.ygyno.2012.01.003 |
11 |
Yang YF , Liao YY , Liu XL , et al. Prognostic factors of regression and relapse of complex atypical hyperplasia and well-differentiated endometrioid carcinoma with conservative treatment[J]. J Gynecol Oncol, 2015, 139 (3): 419- 423.
doi: 10.1016/j.ygyno.2015.10.015 |
12 |
Zhou H , Cao D , Yang J , et al. Gonadotropin-releasing hormone agonist combined with a levonorgestrel-releasing intrauterine system or letrozole for fertility-preserving treatment of endometrial carcinoma and complex atypical hyperplasia in young women[J]. Int J Gynecol Cancer, 2017, 27 (6): 1178- 1182.
doi: 10.1097/IGC.0000000000001008 |
13 |
Pronin SM , Novikova OV , Andreeva JY , et al. Fertility-sparing treatment of early endometrial cancer and complex atypical hyperplasia in young women of childbearing potential[J]. Int J Gynecol Cancer, 2015, 25 (6): 1010- 1014.
doi: 10.1097/IGC.0000000000000467 |
14 |
Dursun P , Erkanli S , Güzel AB , et al. A Turkish Gynecologic Oncology Group study of fertility-sparing treatment for early-stage endometrial cancer[J]. Int J Gynaecol Obstet, 2012, 119 (3): 270- 273.
doi: 10.1016/j.ijgo.2012.06.010 |
15 |
Mitsuhashi A , Habu Y , Kobayashi T , et al. Long-term outcomes of progestin plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer patients[J]. J Gynecol Oncol, 2019, 30 (6): e90.
doi: 10.3802/jgo.2019.30.e90 |
16 | 柳晓肃, 郭红燕, 宋雪凌, 等. 早期高分化子宫内膜癌及子宫内膜不典型增生患者保留生育功能治疗的结局分析[J]. 实用妇产科杂志, 2020, 36 (9): 685- 689. |
17 |
Pashov AI , Tskhay VB , Ionouchene SV , et al. The combined GnRH-agonist and intrauterine levonorgestrel-releasing system treatment of complicated atypical hyperplasia and endometrial cancer: A pilot study[J]. Gynecol Endocrinol, 2012, 28 (7): 559- 561.
doi: 10.3109/09513590.2011.649813 |
18 |
Kim MK , Seong SJ , Kim YS , et al. Combined medroxyproges-terone acetate/levonorgestrel-intrauterine system treatment in young women with early-stage endometrial cancer[J]. Am J Obstet Gynecol, 2013, 209 (4): 358.e1- e4.
doi: 10.1016/j.ajog.2013.06.031 |
19 |
Cade TJ , Quinn MA , Rome RM , et al. Progestogen treatment options for early endometrial cancer[J]. BJOG, 2010, 117 (7): 879- 884.
doi: 10.1111/j.1471-0528.2010.02552.x |
20 |
Zhang Z , Huang H , Feng F , et al. A pilot study of gonadotropin-releasing hormone agonist combined with aromatase inhibitor as fertility-sparing treatment in obese patients with endometrial cancer[J]. J Gynecol Oncol, 2019, 30 (4): e61.
doi: 10.3802/jgo.2019.30.e61 |
21 | Gallos ID , Yap J , Rajkhowa M , et al. Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and metaanalysis[J]. Am J Obstet Gynecol, 2012, 207 (4): 261- 266. |
[1] | 梁丽,李鑫,农琳,董颖,张继新,李东,李挺. 子宫内膜癌微卫星不稳定性分析: 微小微卫星变换的意义[J]. 北京大学学报(医学版), 2023, 55(2): 254-261. |
[2] | 孙希雅,陈艺璐,曾琳,闫丽盈,乔杰,李蓉,智旭. 不孕女性维生素D水平与抗苗勒氏管激素的相关性及对妊娠结局的预测[J]. 北京大学学报(医学版), 2023, 55(1): 167-173. |
[3] | 陈素华,杨军,陈新,杨辰龙,孙建军,林国中,于涛,杨欣,韩芸峰,吴超,司雨,马凯明. 大型、巨大型上矢状窦中后1/3侵犯颅外复发脑膜瘤的手术治疗[J]. 北京大学学报(医学版), 2022, 54(5): 1006-1012. |
[4] | 王跃,张爽,张虹,梁丽,徐玲,程元甲,段学宁,刘荫华,李挺. 激素受体阳性/人表皮生长因子受体2阴性乳腺癌临床病理特征及预后[J]. 北京大学学报(医学版), 2022, 54(5): 853-862. |
[5] | 张红霞,杨蕊,杨硕,潘宁宁,王琳琳,李蓉. 经腹胎儿颅内与胸腔内注射氯化钾减胎的临床效果[J]. 北京大学学报(医学版), 2022, 54(5): 943-947. |
[6] | 陈阳阳,周玉博,杨静,花语蒙,原鹏波,刘爱萍,魏瑗. 双胎妊娠孕期体质量对血清高敏C反应蛋白与妊娠期糖尿病关联的影响:一项队列研究[J]. 北京大学学报(医学版), 2022, 54(3): 427-433. |
[7] | 于博,赵扬玉,张喆,王永清. 妊娠合并感染性心内膜炎1例[J]. 北京大学学报(医学版), 2022, 54(3): 578-580. |
[8] | 刘磊,秦艳春,王国良,张树栋,侯小飞,马潞林. 嗜铬细胞瘤和副神经节瘤二次手术策略[J]. 北京大学学报(医学版), 2021, 53(4): 793-797. |
[9] | 郭洪萍,赵艾,薛勇,马良坤,张玉梅,王培玉. 孕期营养素摄入与妊娠期糖尿病孕妇血糖控制效果的相关性研究[J]. 北京大学学报(医学版), 2021, 53(3): 467-472. |
[10] | 宋沁峰,李宏田,杨静,原鹏波,程志浩,刘建蒙,赵扬玉. 双胎妊娠孕早期甲状腺功能及其与早产的关联性[J]. 北京大学学报(医学版), 2021, 53(3): 473-478. |
[11] | 于焕斌,伍文杰,吕晓鸣,石妍,郑磊,张建国. 125I粒子近距离治疗外放疗后复发唾液腺癌[J]. 北京大学学报(医学版), 2020, 52(5): 919-923. |
[12] | 熊盛炜,王杰,朱伟杰,程嗣达,张雷,李学松,周利群. 二次肾盂成形术在复发性肾盂输尿管连接部梗阻中的研究进展[J]. 北京大学学报(医学版), 2020, 52(4): 794-798. |
[13] | 孟文颖,黄琬桐,张杰,焦明远,金蕾,靳蕾. 孕早期血清维生素E水平与妊娠期高血压疾病发病风险的关系[J]. 北京大学学报(医学版), 2020, 52(3): 470-478. |
[14] | 王晓,贺丹,李文婷,阿迪拉·斯依提,韩蕊,董颖. 144例维吾尔族与汉族女性子宫内膜癌微小RNA表达特点及临床意义[J]. 北京大学学报(医学版), 2020, 52(3): 570-577. |
[15] | 侯磊,叶国华,刘筱菁,李自力. 下颌后缩伴颞下颌关节重度骨关节病患者正颌术后颌骨稳定性及髁突体积变化的评价[J]. 北京大学学报(医学版), 2020, 52(1): 113-118. |
|